Janux Therapeutics, Inc. (JANX): Price and Financial Metrics
GET POWR RATINGS... FREE!
JANX Stock Price Chart Interactive Chart >
JANX Price/Volume Stats
|Current price||$11.72||52-week high||$37.99|
|Prev. close||$11.00||52-week low||$9.39|
|Day high||$11.86||Avg. volume||80,227|
|50-day MA||$12.72||Dividend yield||N/A|
|200-day MA||$19.02||Market Cap||487.89M|
Janux Therapeutics, Inc. (JANX) Company Bio
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. It is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. The company was incorporated in 2017 and is headquartered in La Jolla, California.
Most Popular Stories View All
JANX Latest News Stream
|Loading, please wait...|
JANX Latest Social Stream
View Full JANX Social Stream
Latest JANX News From Around the Web
Below are the latest news stories about Janux Therapeutics Inc that investors may wish to consider to help them evaluate JANX as an investment opportunity.
SAN DIEGO, January 05, 2022--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that Janux management will participate in a fireside chat at the virtual H.C. Wainwright BioConnect Conference being held January 10 to 13.
Janux Therapeutics, Inc. (NASDAQ:JANX)s stock price traded down 13.8% during mid-day trading on Tuesday . The company traded as low as $17.07 and last traded at $17.07. 2,441 shares traded hands during trading, a decline of 99% from the average session volume of 176,950 shares. The stock had previously closed at $19.80. Separately, Zacks Investment 
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Janux Therapeutics (NASDAQ:JANX) lock-up period is set to expire on Wednesday, December 8th. Janux Therapeutics had issued 11,400,000 shares in its public offering on June 11th. The total size of the offering was $193,800,000 based on an initial share price of $17.00. After the end of Janux Therapeutics lock-up period, major shareholders and company insiders  The post Janux Therapeutics, Inc.s (NASDAQ:JANX) Lock-Up Period Will End Tomorrow appeared first on ETF Daily News .
No summary available.
JANX Price Returns